PitchBook’s Q1 2024 Medtech Public Comp Sheet and Valuation Guide

Surgical robotics startups, led by Softbank-backed CMR Surgical, are our picks for the medtech IPO vanguard when the window opens. The subsector has held strong within the industry, and the stocks of similar less-profitable yet higher-growth companies have drawn investor interest. In general, public medtech valuations have steadied after a drawn-out decline, and EBITDA multiples are on the rise in the medical devices, consumer health, and life sciences segments. PitchBook’s Q1 2024 Medtech Public Comp Sheet and Valuation Guide tracks stock performance, EBITDA margins, revenue growth, and valuations for key publicly traded companies.

Read the full article: PitchBook’s Q1 2024 Medtech Public Comp Sheet and Valuation Guide //

Source: https://pitchbook.com/news/reports/q1-2024-medtech-public-comp-sheet-and-valuation-guide

Leave a Comment

Your email address will not be published.

Scroll to Top